Several national reference laboratories, including LabCorp, Quest Diagnostics, ARUP Labs, Mayo Laboratories, and Athena Diagnostics, have commercially-available tests for specific biomarkers for assessing AD. Some of these test offerings measure a combination or panel of biomarkers. In addition, several diagnostic kit manufacturers, such as Roche Diagnostic and Fujirebio Diagnostics, have recently been given FDA approvals as a “Breakthrough Devise,” which is a process designed to expedite the development and review of devices that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. This course will highlight tests available from LabCorp, Quest Diagnostics, and Athena Diagnostics, as well as FDA approvals for Breakthrough Devise tests for AD.
